Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Adverum Biotechnologies, Inc. (NASDAQ: ADVM).

Full DD Report for ADVM

You must become a subscriber to view this report.


Recent News from (NASDAQ: ADVM)

Adverum Biotechnologies Appoints Mike Fitzgerald as Vice President, Human Resources
MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced the appointment of Mike Fitzgerald as vice president, human resources.&...
Source: GlobeNewswire
Date: December, 03 2018 16:10
Adverum Biotechnologies Announces Publication of Preclinical Long-Term Expression and Efficacy Data in Molecular Therapy
MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced the publication of preclinical long-term expression and efficacy data i...
Source: GlobeNewswire
Date: December, 03 2018 08:30
Healthcare and Tech top list of midday movers (11/02/2018)
More news on: Pacific Biosciences of California, Emerge Energy Services LP, VivoPower International PLC, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: November, 02 2018 12:47
JPMorgan and Barclays bearish on Puma in premarket healthcare analyst action
Abiomed (NASDAQ: ABMD ) upgraded to Buy with a $450 (19% upside) price target at BTIG Research after yesterday's fiscal Q2 beat. Shares up a fraction premarket. More news on: ABIOMED, Inc., Emergent BioSolutions Inc., Adverum Biotechnologies, Inc., Healthcare stocks news, Stocks on the mov...
Source: SeekingAlpha
Date: November, 02 2018 07:59
Adverum -29.7% as it ends therapy for A1AT deficiency
Adverum (NASDAQ: ADVM ) has slid 29.7% after hours after a program update says it's going to end development of its gene therapy for A1AT deficiency . More news on: Adverum Biotechnologies, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: November, 01 2018 18:23
Adverum Biotechnologies Provides Program Updates
Preliminary data from the ADVANCE Phase 1/2 Study in A1AT deficiency showed ADVM-043 in doses of up to 1.5 x 10 13  vg/kg were safely administered and well tolerated; Protein expression did not meet a clinically meaningful level Company to provide update on rare disease programs...
Source: GlobeNewswire
Date: November, 01 2018 16:15
Adverum Biotechnologies Announces Appointment of Leone Patterson as CEO and Member of the Board of Directors
MENLO PARK, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the promotion of Leone Patterson as the Company’s president and...
Source: GlobeNewswire
Date: October, 17 2018 16:10
Adverum Bio's gene therapy ADVM-022 shows positive action in preclinical wet AMD study
Results from a preclinical study evaluating Adverum Biotechnologies' ( ADVM -0.4% ) gene therapy ADVM-022 in a non-human primate model of wet age-related macular degeneration (wet AMD) showed an encouraging treatment effect. The data were presented at the ESGCT Congress in Switzerland. ...
Source: SeekingAlpha
Date: October, 17 2018 10:06
Adverum Biotechnologies Announces Data Presented at the European Society of Gene and Cell Therapy (ESGCT)
A single intravitreal injection of ADVM-022 in non-human primates (NHP) demonstrated durable expression of aflibercept sustained out to 22 months In an NHP model, ADVM-022 provided ocular expression of aflibercept at therapeutic levels equivalent to current standard of care MENLO ...
Source: GlobeNewswire
Date: October, 17 2018 09:00
Consolidated Research: 2018 Summary Expectations for Mimecast, Shiloh Industries, Adverum Biotechnologies, AngioDynamics, Kimball Electronics, and Changyou - Fundamental Analysis, Key Performance Indications
NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Mimecast Limited (NASDAQ:MIME), Shiloh Industries, Inc. (NASDAQ:SHLO),...
Source: GlobeNewswire
Date: October, 16 2018 08:40

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-113.783.693.813.59560,447
2018-12-103.623.673.713.57161,549
2018-12-073.623.633.693.59164,821
2018-12-063.573.673.673.56242,360
2018-12-053.763.653.863.62335,913

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-112,0757,42127.9612Cover
2018-12-108,10145,06117.9779Cover
2018-12-0740,10954,21973.9759Short
2018-12-0650,012109,06545.8552Short
2018-12-0438,323100,90137.9808Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ADVM.


About Adverum Biotechnologies, Inc. (NASDAQ: ADVM)

Logo for Adverum Biotechnologies, Inc. (NASDAQ: ADVM)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ADVM)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: May, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 03 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 20 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 20 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 16 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 23 2018
      Amendment to a previously filed 8-K
      Filing Type: 8-K/AFiling Source: edgar
      Filing Date: March, 22 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 06 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 22 2018

       

       


      Daily Technical Chart for (NASDAQ: ADVM)

      Daily Technical Chart for (NASDAQ: ADVM)


      Stay tuned for daily updates and more on (NASDAQ: ADVM)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ADVM)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ADVM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ADVM and does not buy, sell, or trade any shares of ADVM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/